The National Bleeding Disorders Foundation (NBDF), a leading nonprofit supporting people with bleeding disorders, is proud to congratulate Matthew Delaney, government relations manager, on being named to City & State New York’s 2026 Albany 40…
CSL Behring, the biopharmaceutical company behind the hemophilia B gene therapy HEMGENIX ® (etranacogene dezaparvovec-drlb), announced on March 17, 2026, a temporary global stockout of the therapy. This disruption means that some individuals in…
NBDF invites all people who are dedicated to working to achieve greater health equity in the inheritable blood and bleeding disorders community to attend the free Health Equity Virtual Summit on May 11-12th, 2026. With the theme of “Every Hour,…
CHAPTER 1 – Iron Deficiency with and without Anemia in the Inherited Bleeding Disorders Population Experts: Glaivy Batsuli1; Magdalena D. Lewandowska2; Ming Y. Lim3; Amy Dunn4; Kelly…
The National Bleeding Disorders Foundation (NBDF) is excited to announce new 2026 scholarship opportunities available to the bleeding disorders community.Kevin Child Scholarship (KCS)The KCS awards $1,000 to eligible individuals…
Speakers: Ben Samelson-Jones, MD, PhD, Children's Hospital of Philadelphia; Halli Benasutti, PhD, NBDF; Bill Maurits Current gene therapy approaches for hemophilia A have been limited by suboptimal durability and inability to…
The National Bleeding Disorders Foundation (NBDF) is alerting the community to updated information from Takeda Pharmaceutical Company regarding the discontinuation timelines for HEMOFIL® M and RECOMBINATE®, two therapies used to treat hemophilia A,…